DC-HIL in cancer

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: PONCIANO D CRUZ
Organization: VA NORTH TEXAS HEALTH CARE SYSTEM
Fiscal Year: 2024
Funding agency: Veterans Affairs

PROJECT SUMMARY
Melanoma is a significant cause of morbidity and mortality in the U.S. and among
military veterans. Having discovered an immune-vascular regulating pathway (DC-
HIL/SD4) whose function can be manipulated to treat cancers, we will: (1) dissect its
effects on immunity and vascularity in melanoma; (2) develop treatment targeted at a
key carbohydrate component of the pathway; and (3) characterize changes in this
component during melanoma growth and metastasis. Our results will improve current
management of metastatic melanoma and potentially other cancers.

Terms: <Ablation><Angiogenesis Factor><Angiogenesis Pathway><Angiogenic Factor><Antigenic Determinants><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B7-H1><B7H1><Basic Fibroblast Growth Factor><Basic Fibroblast Growth Factor Gene><Binding><Binding Determinants><Bioassay><Biological Assay><Blood Vessels><Body Tissues><CD152><CD152 Antigen><CD152 Gene><CD274><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancers><Carbohydrates><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Checkpoint inhibitor><Chemotactic Cytokines><Clinical Treatment Moab><Cre Lox technology><Cre LoxP system><Cre lox recombination><Cre lox recombination system><Cre lox system><Cre recombinase/LoxP technology><Cre system><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Endothelial Cells><Epitopes><Extravasation><FGF-2><FGF2><FGF2 gene><FGFB><Fibroblast Growth Factor 2><Fibroblast Growth Factor 2 Gene><Fibroblasts><Generalized Growth><Genes><Genetic Alteration><Genetic Change><Genetic defect><Glycans><Growth><HBGF-2><HSPG><Heparan Sulfate><Heparan Sulfate Biosynthesis><Heparan Sulfate Proteoglycan><Heparin-Binding Growth Factor 2><Heparin-Binding Growth Factor Class II><Heparitin Sulfate><Heterograft><Heterologous Transplantation><Histology><Homologous Chemotactic Cytokines><Human><Immune><Immune Precipitation><Immune checkpoint inhibitor><Immunes><Immunity><Immunoprecipitation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Impairment><Implant><Infusion><Infusion procedures><Intercrines><Intracellular Communication and Signaling><Leakage><Leucocytic infiltrate><Ligands><Link><Location><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Mediating><Melanoma><Melanoma Cell><Melanoma Metastasis><Melanoma patient><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Melanoma><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><Mice><Mice Mammals><Modality><Modeling><Modern Man><Molecular Interaction><Monoclonal Antibodies><Morbidity><Morbidity - disease rate><Murine><Mus><Mutation><Neoplasm Metastasis><Oligosaccharides><Oranges><Outcome><PD-L1><PD-L1 therapy><PD-L1 treatment><PDL-1><PDL1><PDL1 therapy><PDL1 treatment><PTK Inhibitors><Pathogenesis><Pathway interactions><Patients><Pattern><Polysaccharides><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Property><Prostate Epithelial Cell Growth Factor><Protein Tyrosine Kinase Inhibitors><Proteoglycan><Proteoheparan Sulfate><Receptor Protein><Resistance><SIS cytokines><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Spillage><Sulfate><T Chain><T cell response><T-Cells><T-Lymphocyte><TK Inhibitors><Tamoxifen><Testing><Tissue Growth><Tissues><Tumor Angiogenesis><Tyrosine Kinase Inhibitor><VEGF><VEGF, Hypoxia, and Angiogenesis><VEGFs><Vascular Endothelial Growth Factors><Xenograft><Xenograft procedure><Xenotransplantation><aPD-L1><aPD-L1 therapy><aPD-L1 treatment><aPDL1><angiogenesis><anti programmed cell death ligand 1><anti programmed cell death ligand 1 therapy><anti programmed cell death ligand 1 treatment><anti programmed cell death protein ligand 1><anti programmed cell death protein ligand 1 therapy><anti programmed cell death protein ligand 1 treatment><anti-PD-(L)1><anti-PD-L1><anti-PD-L1 therapy><anti-PD-L1 treatment><anti-PDL-1><anti-PDL1><anti-PDL1 therapy><anti-PDL1 treatment><antiPD-L1><antiPDL1><bFGF><biological signal transduction><cancer metastasis><cancer progression><chemoattractant cytokine><chemokine><cytotoxic T-lymphocyte antigen 4><effective therapy><effective treatment><genome mutation><immune check point><immune check point inhibitor><immune checkpoint><immune suppression><immune suppressive activity><immune suppressive function><immunecheckpoint><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><in vivo><infusions><lung metastasis><mAbs><malignancy><metastasize to the lung><military veteran><monoclonal Abs><mortality><mouse model><murine model><neoplasm progression><neoplasm/cancer><neoplastic progression><novel><ontogeny><pathway><programmed cell death ligand 1><programmed cell death protein ligand 1><protein death-ligand 1><pulmonary metastasis><receptor><resistant><subcutaneous><subdermal><syndecan-4><syndecan4><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><thymus derived lymphocyte><tumor><tumor cell metastasis><tumor growth><tumor progression><vascular><veteran population><xeno-transplant><xeno-transplantation><αPD-L1><αPD-L1 therapy><αPD-L1 treatment><αPDL1>